Pfizer’s US Contract Sets The Financial Bar For COVID-19 Vaccines

The US government’s order of 100 million doses for $1.95bn means the implied price for Pfizer/BioNtech's vaccine is $19.50 per dose. That could set a benchmark for solid near-term revenue and profitability for companies in the space.

profit text written on wooden block with stacked coins on grey background — Pfizer's appears poised to make a solid profit off of a COVID-19 vaccine • Source: Shutterstock

While the race to get a COVID-19 vaccine to market remains tight, Pfizer Inc. and BioNTech SE are leading the way when it comes to pricing. Their COVID-19 vaccine supply agreement with the US government for 100 million doses for $1.95bn sets a bar for implied pricing and profitability for vaccine players working in the space.

The companies and the US Department of Health and Human Services announced an agreement on 22 July under which the implied price for the vaccine would be $19

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.